Docusign Envelope ID: 7EFE37F0-3285-8783-829E-218BE5C57E0B

EVENT SPONSORSHIP AGREEMENT

This sponsorship agreement ("**Agreement**") is effective as of the 3 September 2026 ("**Effective Date**") and is entered by and between:

BeOne Medicines International GmbH - Denmark Branch a company incorporated under the laws of Denmark whose registered office is at c/o TMF Denmark, Købmagergade 60, 1 sal tv, Copenhagen K 1150, Denmark ("**Company**")

and

LYLE - PATIENTFORENINGEN FORLYMFEKRÆFT, LEUKÆMI OG MDS a non-for-profit institution incorporated under the laws of whose registered office is at Banetoften 26, Næstved 4700, Denmark ("**Recipient**")

WHEREAS, Company is a biotechnology company that develops and commercializes biopharmaceutical products;

WHEREAS Recipient is a non-for profit or profit organization that wish to organize the event described in Article 1 of the Agreement and has requested funding support.

WHEREAS Company after receiving Recipient request, which is attached as annex 1, has agreed to provide support to the Event as described below.

NOW THEREFORE in connection therewith and in consideration thereof, Recipient and Company agree as follows:

1. Company will provide Recipient with seventy-seven thousand five hundred (27.500) DKK ("**Support**") which shall be used by Recipient for the event described in this Article 1 ("**Event**") and Company will receive the sponsorship benefits described in this Article 1.

   Sponsorshift
   Patient-oriented booklet about Waldenstrøm Syndrome

   These will be available for distribution at Hematology outpatient clinics, in volunteer centres, the Danish Cancer Society, at patient events and in general practice, etc.

   The booklets will also be available to LYLE members via a small printed edition (for distribution to members) and also via printable PDF formats that can be downloaded from lyle.dk.

2. Payment of the Support shall be made by Company to the bank account of Recipient identified on the invoice received from Recipient within sixty (60) days. The invoices must display any applicable VAT amount separately.

3. Recipient shall transparently disclose that Company has provided Support for the Event. Company shall have the right to publish the name of Recipient and the details of the Support and Event in order to comply with transparency reporting requirements. Such reporting may include the name of any relevant healthcare

Docusign Envelope ID: 7EFE37F0-3285-8783-829E-218BE5C57E0B

professional (HCP) who was a presenter at the Event and was paid at fair market value for his or her contribution to the Event.

4. Company shall have no control or influence over the content of the Event. Company does not agree, recommend, obtain or otherwise provide any details of the attendees that will participate in the Event. If the Event is virtual the Recipient shall use a reputable virtual meeting system that support Secure Conferencing webinar meetings (e.g Zoom Webinar or GoTO).

5. The Parties agree that the sponsorship is not being provided by Company, nor accepted by Recipient, as an inducement to, either now or in the future, purchase, prescribe, promote, or recommend any of Company's products or services.

6. No part of the Support may be paid to any third party, other than as reasonable fair market value compensation for items and services obtained at fair market value provided to Recipient in connection with the Event in accordance with applicable laws, regulations and applicable industry codes of practice (including those pertaining to transparency reporting).

7. No portion of the Support shall be used by the Recipient to provide unlawful benefits to a healthcare professional or to any government employee or official. The Recipient represents and warrants that no person or company working on behalf of the Recipient, shall directly or indirectly, offer, pay, promise to pay, or authorize such offer, promise or payment, of anything of value, to any person or entity for the purposes of obtaining or retaining business or any improper advantage in connection with this Agreement, or that would otherwise violate any applicable laws, rules and regulations concerning or relating to public or commercial bribery or corruption.
   Recipient agrees to comply with all the regulations relating to Anti-Bribery, including the United States Foreign Corrupt Practices Act, as amended from time to time, with regard to the Event including not offering or giving anything of value to a foreign public official in connection with the performance of the official's duties or inducing an official to use their position to influence any acts or decisions of any foreign, state or public international organization.
   Additionally, Recipient agrees to comply with the UK Antibribery Act.

8. The Recipient is free to seek funding from other companies. If any additional funding reaches a level such that all or part of the Support is no longer required by the Recipient, the Recipient shall refund such amount of the Support that is no longer required. Recipient shall return any unused funds provided by Company or any amounts not used in accordance with the terms and conditions of this Agreement:
   - within 30 days from the date of the Event or;
   - within 30 days from the cancellation of the Event or;
   - within 30 days from termination by Company of the Agreement for Recipient breach of the obligations contained in the Agreement.

9. Any discussion of medicinal therapies or test/quizzes/votes concerning Continuing Professional Development (CPD) at the Event shall be non-promotional, balanced, accurate and complete and shall comply with applicable laws and regulations

Docusign Envelope ID: 7EFE37F0-3285-8783-829E-218BE5C57E0B

10. The Event shall be attended by healthcare professionals only

11. Recipient confirms that the selection of the location and timing of the Event is based on one of the following criteria: (i) the majority of the attendees are resident in the country where the Event will take place, or (ii) the attendees at the Event are coming from different countries and, therefore, the Event was selected based on logistical convenience considering the country of residence of the attendees.

12. In the event Recipient becomes aware of an adverse event and/or a product complaint, Recipient shall inform Company´s Safety Operations Group within 24 hours of first becoming aware via adverse_events@beonemed.com and/or productcomplaints@beonemed.com.

13. If attendees require proof of attendance to the Event, the Recipient is solely responsible for providing such proof and/or CPD education records, and shall comply with all applicable data privacy law requirements and necessary consents (and any transparency disclosures as contemplated under section 3 of this Agreement) to process such requests, including but not limited to ensuring the Event qualifies as a recognised course and is code compliant with the relevant medical association, where applicable.

14. Recipient shall keep and maintain until ten (10) years after the Event have been completed full and accurate records relating to (i) the Event and the Support; (ii) all expenditure reimbursed by the Recipient; and (iii) all payments to any third party (HCPs included) made by the Recipient in connection with this Agreement. To ensure compliance with any applicable laws and regulations by Company, Recipient shall promptly on request afford Company or Company's representatives' access to all records relating to (i), (ii) and (iii) above at Company's expenses. Such records shall be made available to Company during normal business hours at the Recipient's office or place of business or, in the event that no such location is reasonably available, via email.

15. The Parties will process all personal data (as defined in applicable data protection laws) obtained during the course of the Event in accordance with the applicable data protection laws.

    Company will only process any personal data received from the Recipient in order to enter into or perform this Agreement. Recipient warrants that it shall limit the personal data disclosed to Company to the contact information for individuals involved with this Agreement and shall inform or obtain the prior written consent of each individual, as required by applicable law, for the disclosure of their respective personal data to Company and processing in accordance with this clause. The parties understand that Company will not have any further information/consent obligations towards the Recipient's personnel.

16. This Agreement shall commence on the Effective Date and shall automatically terminate two (2) months from the date of the completion of the Event.

17. In the event of a conflict between the provisions in the main body of this Agreement and any annex or attachment hereto, the provisions of this Agreement will control.

Docusign Envelope ID: 7EFE37F0-3285-8783-829E-218BE5C57E0B

18. The parties agree that this Agreement will be governed by and interpreted under the laws of Denmark. Any dispute arising out of this Agreement shall be submitted to the exclusive jurisdiction of the competent courts of Copenhagen, Denmark.

19. This Agreement may be executed in counterparts all of which taken together shall constitute one agreement and copies may be exchanged electronically, such as by e-mail (e.g. PDF) and such electronic copy of the signed document will be considered valid and binding on the signing Party.

BeOne Medicines International GmbH - Denmark Branch

DocuSigned by:
Astrid Ottosson Wadlund
902BE8EDF5D84AE...

Name (CAPS): ASTRID OTTOSSON WADLUND

Title: Medical Director Nordics

Date: 03-Sep-2026

LYLE - PATIENTFORENINGEN FORLYMFEKRÆFT, LEUKÆMI OG MDS

DocuSigned by:
Rita Christensen
F92DBD4EBA834E6...

Name (CAPS): RITA. O. CHRISTENSEN

Title: Chair

Date: 07-sep-2026

Docusign Envelope ID: 7EFE37F0-3285-8783-829E-218BE5C57E0B

Annex 1 - Original Request for Support/Sponsorship Benefits

Patientforeningen for
Lymfekræft, Leukæmi og MDS

Ansøgning til BeOne, Danmark

LyLe ønsker at få en patientrettet pjece om Waldenstrøms Syndrom

I LyLe lægger vi vægt på at kunne tilbyde vores medlemmer og andre interesserede patientnære, sygdomsspecifikke informationshæfter om blodkræftsygdomme som her Waldenstrøms. Disse skal ligge til udlevering på de hæmatologiske ambulatorier, i frivillighedshuse, Kræftens Bekæmpelse, ved patientarrangementer og i almen praksis m.m.

Hæfterne skal desuden være tilgængelige for LyLe's medlemmer via et mindre trykt oplag (til uddeling til medlemmer) og i øvrigt via printbare PDF-formater, der kan hentes på lyle.dk.

Vi har et stort ønske om en pjece om Waldenstrøms og meget interesseret i at voksende antal af medlemmer og patienter med Waldenstrøms bliver opdaterede. I nyere tid er der sket en udvikling af nyere behandling, som vi ønsker at belyse. Teksten udarbejdes i samarbejde med hæmatolog Michael Tøstesen fra Aarhus/Gødstrup.

Folderen om Waldenstrøms er inspireret af tilsvarende folder:
https://lyle.dk/product/cll-symptomer-diagnose-og-behandling-folder/

Docusign Envelope ID: 7EFE37F0-3285-8783-829E-218BE5C57E0B

Budgetestimat:

	Pris ekskl. moms	Pris inkl. moms
Tekstproduktion (fritaget moms)	11.000 DKK	11.000 DKK
Layout	6.000 DKK	7.500 DKK
Tryk, 500 styk	3.000 DKK	3.750 DKK
Opsætning til hjemmesiden	3.750 DKK	5.000 DKK
I alt, estimeret		27.250 DKK

Mange hilsner fra

Rita O. Christensen
Formand

LyLe – Patientforeningen for Lymfekræft, Leukæmi og MDS
Banetoften 26 · 4700 Næstved · tlf. 31 68 26 00 · CVR 31 30 68 33 · lyle@lyle.dk · www.lyle.dk